Key result
In patients with stage 3 to 4 CKD, a 0.1 μmol/L increase in plasma ADMA level was associated with a 37% increased risk of all-cause death, nonfatal MI, and stroke.
Why the study?
Elevated plasma ADMA levels have been associated with endothelial dysfunction and cardiovascular risk in ESRD, but their association with long-term outcomes in stage 3 to 4 CKD patients was unclear.
Does elevated plasma ADMA level predict composite outcomes of all-cause death, nonfatal MI, and stroke in patients with stage 3 to 4 CKD?
Cohort (n=298)
Does elevated plasma ADMA level predict composite outcomes of all-cause death, nonfatal MI, and stroke in patients with stage 3 to 4 CKD?
Answers are grounded in this paper and cite their sources.
Elevated plasma ADMA levels serve as an independent predictor of long-term adverse cardiovascular outcomes and mortality in elderly, high-risk patients with stage 3 to 4 CKD.
BACKGROUND AND OBJECTIVES: Elevated plasma level of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction and atherosclerosis risk factors, and may predict cardiovascular events in patients with ESRD. In this study, we aimed to assess the association between plasma ADMA and long-term outcome in a cohort of patients with stage 3 to 4 chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From July 2006 to June 2009, 298 consecutive patients with stage 3 to 4 CKD scheduled to undergo coronary angiography were recruited. Plasma ADMA levels were determined using HPLC. RESULTS: The mean age was 73 ± 10 years. Approximately half of the patients had diabetes and 88 patients had proteinuria. The baseline estimated GFR (eGFR) was 44 ± 13 ml/min per 1.73 m². The plasma ADMA levels of the patients with proteinuria were significantly higher than those without. The plasma ADMA levels correlated significantly with eGFR. During the median follow-up period of 2.7 years, we observed 26 all-cause deaths, 12 nonfatal myocardial infarctions, and 2 strokes. Multivariate Cox analysis revealed that an increase of 0.1 μmol/L in plasma ADMA level was associated with a 37% increased risk of the composite outcomes of all-cause deaths, nonfatal myocardial infarctions, and strokes. CONCLUSIONS: In this elder and high-risk population with stage 3 to 4 CKD, high plasma ADMA level was associated with low eGFR and macroalbuminuria. Furthermore, high plasma ADMA level appeared to be an independent predictor of long-term outcome.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2011) conducted a cohort in Stage 3 to 4 chronic kidney disease (CKD) (n=298). Plasma asymmetric dimethylarginine (ADMA) vs. Lower ADMA levels was evaluated on Composite of all-cause deaths, nonfatal myocardial infarctions, and strokes (37% increased risk per 0.1 μmol/L increase). In patients with stage 3 to 4 CKD, a 0.1 μmol/L increase in plasma ADMA level was associated with a 37% increased risk of all-cause death, nonfatal MI, and stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: